

**Professor Birgitte Vrou Offersen, MD, PhD**

**University of Aarhus, Denmark**

Birgitte Vrou Offersen is a professor of Breast Cancer Clinical Oncology at the Department of Experimental Clinical Oncology, Department of Oncology & Danish Centre for Particle Therapy, at Aarhus University Hospital, Denmark. Her PhD degree was on tumor microenvironment and angiogenesis in solid cancers, but the clinical interest as a clinical oncologist turned towards radiation therapy (RT). The aim of her research is on gains and risks from RT of early breast cancer patients, both investigating the indication for breast cancer RT and the risk of late effects. Research interests include e.g. translational research, fractionation, indications for RT, RT technical aspects, patient involvement, unequal access to RT, proton therapy.

BVO is chair of the Danish Breast Cancer Group (DBCG) Board & the DBCG RT Committee and strongly focused on conducting practice-changing clinical trials for early breast cancer patients. She is principal investigator for 5 national and international clinically controlled phase III randomized trials: the DBCG HYPO trial, the DBCG PBI trial, the DBCG Skagen trial 1, the DBCG RT Natural trial and the DBCG Proton trial.

BVO is breast editor of the Radiotherapy & Oncology journal, and she is part of the teaching faculty of the ESTRO breast courses.